GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice

• Published in: PloS one 2020-01, Vol.15 (1), p.e0228408-e0228408
• Main Authors: Friend, Natasha, Noll, Jacqueline E, Opperman, Khatora S, Clark, Kimberley C, Mrozik, Krzysztof M, Vandyke, Kate, Hewett, Duncan R, Zannettino, Andrew C W
• Format: Article
• Language: English
• Subjects: Aging; Amyloidosis; Animals; Apoptosis; B cells; Biology and Life Sciences; Biotechnology; Cell cycle; Cell Line, Tumor; Cell Proliferation; CRISPR; Diseases; Down-Regulation; EDTA; Epigenetics; Funding; Gene Editing; Gene expression; Gene Expression Regulation, Neoplastic; Genes; Genetic factors; Genome editing; Genomes; Genomics; House mouse; Humans; Immunoglobulins; Male; Malignancy; Medical research; Medical schools; Medicine and Health Sciences; Mice; Multiple myeloma; Multiple Myeloma - genetics; Multiple Myeloma - pathology; Mutation; Neoplasm Proteins - genetics; Neoplasm Transplantation; Nerve Tissue Proteins - genetics; Plasma cells; Precision medicine; Prostate cancer; Research and Analysis Methods; Scholarships & fellowships; Scientific equipment industry; Tumors
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0228408

Multiple myeloma, a plasma cell malignancy, is a genetically heterogeneous disease and the genetic factors that contribute to its development and progression remain to be fully elucidated. The tumour suppressor gene GLIPR1 has previously been shown to be deleted in approximately 10% of myeloma patients, to inhibit the development of plasma cell tumours in ageing mice and to have reduced expression levels in the plasma cells of patients with light-chain amyloidosis, a myeloma-related malignancy. Therefore, we hypothesised that GLIPR1 may have tumour suppressor activity in multiple myeloma. In this study, we demonstrate that plasma cell expression of GLIPR1 is reduced in the majority of myeloma patients and Glipr1 expression is lost in the 5TGM1 murine myeloma cell line. However, overexpression of GLIPR1 in a human myeloma cell line did not affect cell proliferation in vitro. Similarly, re-expression of Glipr1 in 5TGM1 cells did not significantly reduce their in vitro proliferation or in vivo growth in C57BL/KaLwRij mice. In addition, using CRISPR-Cas9 genome editing, we generated C57BL/Glipr1-/- mice and showed that loss of Glipr1 in vivo did not affect normal haematopoiesis or the development of monoclonal plasma cell expansions in these mice up to one year of age. Taken together, our results suggest that GLIPR1 is unlikely to be a potent tumour suppressor in multiple myeloma. However, it remains possible that the down-regulation of GLIPR1 may cooperate with other genetic lesions to promote the development of myeloma.